deltatrials
Completed PHASE1/PHASE2 INTERVENTIONAL 1-arm NCT01976585

In Situ Vaccine for Low-Grade Lymphoma: Combination of Intratumoral Flt3L and Poly-ICLC With Low-Dose Radiotherapy

A Phase I/II Study of Intratumoral Injection of rhuFlt3L/CDX-301 and Poly-ICLC in Combination With Low-Dose Radiotherapy in Low-Grade B-cell Lymphomas

Sponsor: Celldex Therapeutics

Conditions Low-Grade B-cell Lymphoma
Interventions Poly-ICLC rhuFlt3L/CDX-301
Updated 11 times since 2017 Last updated: Sep 21, 2022 Started: Jan 3, 2014 Primary completion: Nov 20, 2020 Completion: Nov 20, 2020
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT01976585, this PHASE1/PHASE2 trial focuses on Low-Grade B-cell Lymphoma and remains completed. Sponsored by Celldex Therapeutics, it has been updated 11 times since 2014, reflecting substantial change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

~Jan 2017 – ~Feb 2017 · 31 days · monthly snapshotRecruiting~Feb 2017 – ~Jun 2018 · 16 months · monthly snapshotRecruiting~Jun 2018 – ~Nov 2018 · 5 months · monthly snapshotRecruiting~Nov 2018 – ~Feb 2019 · 3 months · monthly snapshotRecruiting~Feb 2019 – ~Mar 2020 · 13 months · monthly snapshotRecruiting~Mar 2020 – ~Dec 2020 · 9 months · monthly snapshotRecruiting~Dec 2020 – ~Jan 2021 · 31 days · monthly snapshotRecruiting~Jan 2021 – ~Sep 2022 · 20 months · monthly snapshotRecruiting~Sep 2022 – ~Jul 2024 · 22 months · monthly snapshotCompleted~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshotCompleted~Sep 2024 – present · 22 months · monthly snapshotCompleted

Change History

11 versions recorded

  1. Sep 2024 — Present [monthly]

    Completed PHASE1/PHASE2

  2. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE1/PHASE2

    Phase: PHASE1_PHASE2 → PHASE1/PHASE2

  3. Sep 2022 — Jul 2024 [monthly]

    Completed PHASE1_PHASE2

    Status: Recruiting → Completed

  4. Jan 2021 — Sep 2022 [monthly]

    Recruiting PHASE1_PHASE2

  5. Dec 2020 — Jan 2021 [monthly]

    Recruiting PHASE1_PHASE2

▶ Show 6 earlier versions

  1. Mar 2020 — Dec 2020 [monthly]

    Recruiting PHASE1_PHASE2

  2. Feb 2019 — Mar 2020 [monthly]

    Recruiting PHASE1_PHASE2

  3. Nov 2018 — Feb 2019 [monthly]

    Recruiting PHASE1_PHASE2

  4. Jun 2018 — Nov 2018 [monthly]

    Recruiting PHASE1_PHASE2

  5. Feb 2017 — Jun 2018 [monthly]

    Recruiting PHASE1_PHASE2

  6. Jan 2017 — Feb 2017 [monthly]

    Recruiting PHASE1_PHASE2

    First recorded

Jan 2014

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Celldex Therapeutics
  • Joshua Brody
Data source: Icahn School of Medicine at Mount Sinai

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations